All In Biotech

Drug Trial Radar · NCT00440843

Zyprexa and Task Engagement in Schizophrenia

Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia

Last checked: Nov 19, 2026Latest source record: Dec 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Feb 2007

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Lead sponsor
VA Connecticut Healthcare SystemFederal agency
Sponsor type
Federal agency
Collaborators
Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital; Eli Lilly and Company
First posted
Feb 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Individuals with schizophrenia frequently have impairments in attention. These impairments have been shown to be related to overall functioning. Some research suggests that Olanzapine may be associated with improvement in various aspects of attention. The primary purpose of this study is to determine whether switching from a typical antipsychotic to Olanzapine improves task engagement. Individuals who taking typical antipsychotics will be randomly assigned to either 1) remain on their typical antipsychotic medications, or 2) be switched from their typical antipsychotic medications to Olanzapine. All participants will be enrolled in a twice-weekly 20 session cognitive training program that is specifically designed to target attention deficits and promote active engagement. Improvements in attention will be compared between individuals who remained on their typical antipsychotic medications and those that were switched to Olanzapine.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder

Interventions

  • Olanzapine (Zyprexa)Drug

    OLZ

  • TypicalsDrug

    Stay on typicals regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PupillometryTime frame: Baseline, post

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.